|
|
Post by jkendra on Sept 13, 2022 20:09:09 GMT -5
|
|
|
|
Post by uvula on Sept 14, 2022 10:16:01 GMT -5
Nice to see any article that mentions afrezza, but it doesn't mention how it cuts overall insulin costs. His "bottle" of insulin lasts longer but he has to pay for the afrezza.
|
|
|
|
Post by mnkdfann on Sept 15, 2022 9:40:59 GMT -5
Nice to see any article that mentions afrezza, but it doesn't mention how it cuts overall insulin costs. His "bottle" of insulin lasts longer but he has to pay for the afrezza. It seems to be arguing that Afrezza may be cheaper overall: "But it’s cheaper than EpiPen, insulin, needles, and everything else you have to buy." Did we all notice the lung warning: "Doctors have questioned if insulin in the lungs a good thing for patients is, but every user has a yearly lung test." |
|
|
|
Post by Chris-C on Sept 15, 2022 14:22:05 GMT -5
Nice to see any article that mentions afrezza, but it doesn't mention how it cuts overall insulin costs. His "bottle" of insulin lasts longer but he has to pay for the afrezza. It seems to be arguing that Afrezza may be cheaper overall: "But it’s cheaper than EpiPen, insulin, needles, and everything else you have to buy." Did we all notice the lung warning: "Doctors have questioned if insulin in the lungs a good thing for patients is, but every user has a yearly lung test." Well, he forgot to mention pulmonary safety data collected on thousands of users, or that if he thought it was risky to prescribe, he wouldn't be prescribing it for his patients. But, whatever. Aspirin would probably have a black box warning too if it were being evaluated as an NDA by the FDA. Nota bene: studyfinds.org/aspirin-dangers-health-risks/ |
|
